Eugenia Jones


After graduating from the University of Chicago, with a Ph.D. from the Committee on Neurobiology, in 1994 where she published works identifying genes encoding neurotransmitter transporters and ion channels, Dr. Jones joined the University of Wisconsin at Madison where she worked for over 13 years in the Departments of Neurophysiology and Physiology. While at the University of Wisconsin Dr. Jones continued her research in molecular mechanisms underlying electrical activity in neural, sensory, and cardiac tissues. During her tenure at the University of Wisconsin, Dr. Jones continued to publish, patent and teach undergraduate, medical school, and graduate courses in basic neuroscience, molecular neurobiology and biophysics. From 2007-2012, Dr. Jones moved into industry to develop approved medical molecular diagnostics platforms and assays for use in hospital as well as drug discovery applications.  While in private industry Dr. Jones received additional business training at the California Institute of Technology Executive Education Center. In 2012, Dr. Jones joined Cellular Dynamics International to establish and expand the MyCell product portfolio; bespoke and catalog solutions and iPSC derived product to model human physiology and patho-physiology. In 2016, Dr. Jones became the Director of Basic and Translational Sciences focused on developing solutions for research in basic mechanism and biomarkers for physiological and pathophysiological states and in 2018 became the Senior Director of Global Marketing and Product Development for the Life Sciences Division.

A platform of hPSC-derived cell culture models-challenges and opportunities

For many human diseases, limited access to tissue from diseased and healthy controls creates substantial barriers for scientists impeding research and drug development.  Human induced pluripotent stem cells (hIPSC) promises to provide a seemingly inexhaustible supply of cells derived from healthy and diseased donors for the study of physiological and patho-physiological states. To realize this promise there must be a trusted supply of high quality hIPSC as well as hIPSC-derived cells. Here we will describe the efforts to establish well-characterized hIPSC. Further we will show how ready access to large scale hIPSC-derived neural cells enables reproducible characterization of disease phenotypes in cellular models across multiple labs. Lastly we will discuss how such findings may be correlated with donor clinical data.